author-photo

Edward C. Keystone

University of Toronto
Mount Sinai Hospital
Mount Sinai Hospital, Toronto

308

Papers

21545

Citations

Citation Trend

Filter By

Papers (207) Sort By

Journal Conference Others

Primary and secondary non-response: in need of operational definitions in observational studies.

2021 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (1)
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.

2021 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (13)
Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19.

2021
Show All
- Source
- Cite
- Save
Citations (0)
P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data

2021 Rheumatology
Show All
- Source
- Cite
- Save
Citations (0)
Health care costs of rheumatoid arthritis: A longitudinal population study.

2021 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (0)
“From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)

2021
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.

2021 Arthritis Research & Therapy
Show All
- Source
- Cite
- Save
Citations (5)
POS0461 RESPONSE TO BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS: RETHINKING OUR CLASSIFICATION

2021 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib.

2020 RMD Open
Show All
- Source
- Cite
- Save
Citations (6)
SAT0046 MODIFIED DISEASE ACTIVITY SCORE AT 3 MONTHS IS A SIGNIFICANT PREDICTOR FOR RAPID RADIOGRAPHIC PROGRESSION AT 12 MONTHS COMPARED WITH OTHER MEASURES

2020 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)